Division of Dermatology and Venereology, University Hospital of Geneva, Geneva, Switzerland.
Division of Laboratory Medicine, University Hospital of Geneva, Geneva, Switzerland.
Microbiol Spectr. 2022 Feb 23;10(1):e0147721. doi: 10.1128/spectrum.01477-21. Epub 2022 Feb 9.
Neurosyphilis (NS) diagnosis is challenging because clinical signs are diverse and unspecific, and a sensitive and specific laboratory test is lacking. We tested the performance of an antibody index (AI) for intrathecal synthesis of specific anti- IgG by enzyme-linked immunosorbent assay (ELISA) for NS diagnosis. We conducted a retroprospective monocentric study including adults with neurological symptoms who had serum and cerebral spinal fluid (CSF) samples collected between 2006 and 2021. Two NS definitions were used. NS1 included patients with neurological symptoms, positive Treponema pallidum particle agglutination (TPPA) serology, and CSF-TPPA of ≥320, as well as CSF-leukocytes of >5 cells/mm and/or CSF-protein of >0.45 g/L and/or a reactive CSF-VDRL/RPR test. NS2 included patients with acute ocular and/or otologic symptoms, positive TPPA serology, and a response to NS treatment. Controls were patients with central nervous system disorders other than neurosyphilis. Anti-Treponema pallidum IgG were measured simultaneously in serum and CSF, and AI was calculated according to Reiber diagram. We assessed the AI test area under the curve (AUC), sensitivity/specificity, and estimated positive and negative predictive values. In total, 16 NS1 patients, 11 NS2 patients, and 71 controls were included. With an AI of ≥1.7 as a positive test for NS diagnostic, specificity was 98.6% (95% confidence interval [CI 95%] of 92.4 to 100.0) and sensitivity was 81.3% (CI 95% of 54.4 to 96.0) for NS1 and 98.6% (CI 95% 92.4 to 100.0) and 27.3% (CI 95% 6.0 to 61.0), respectively, for NS2. Positive and negative predictive values were >95% for NS1 and >85% for NS2, for prevalence above and below 20%. Measuring an AI for intrathecal synthesis of specific anti-Treponema pallidum IgG is a new promising tool highly specific for NS diagnosis. In the context of a lack of a gold standard for the diagnosis of neurosyphilis due to either nonspecific or nonsensitive tests, we present in this article a new promising tool highly specific for NS diagnosis. This new test involves measuring an intrathecal synthesis index of specific anti- IgG by ELISA.
神经梅毒(NS)的诊断具有挑战性,因为临床症状多种多样且不具有特异性,并且缺乏敏感和特异性的实验室检测。我们通过酶联免疫吸附试验(ELISA)检测了特定抗 IgG 鞘内合成的抗体指数(AI)在 NS 诊断中的性能。我们进行了一项回顾性单中心研究,纳入了 2006 年至 2021 年间出现神经系统症状且采集了血清和脑脊髓液(CSF)样本的成年人。采用了两种 NS 定义。NS1 包括具有神经系统症状、阳性梅毒螺旋体颗粒凝集(TPPA)血清学和 CSF-TPPA 大于等于 320,以及 CSF-白细胞大于 5 个/毫米和/或 CSF-蛋白大于 0.45 克/升和/或反应性 CSF-VDRL/RPR 检测的患者。NS2 包括具有急性眼部和/或耳部症状、阳性 TPPA 血清学和对 NS 治疗有反应的患者。对照组为除神经梅毒以外的中枢神经系统疾病患者。同时在血清和 CSF 中测量抗梅毒螺旋体 IgG,并根据 Reiber 图计算 AI。我们评估了 AI 测试的曲线下面积(AUC)、敏感性/特异性,并估计了阳性和阴性预测值。共纳入 16 例 NS1 患者、11 例 NS2 患者和 71 例对照组。当 AI 大于等于 1.7 时作为 NS 诊断的阳性检测,NS1 的特异性为 98.6%(95%置信区间 [CI 95%] 92.4 至 100.0)和敏感性为 81.3%(95%CI 54.4 至 96.0),NS2 的特异性为 98.6%(95%CI 92.4 至 100.0)和敏感性为 27.3%(95%CI 6.0 至 61.0)。NS1 和 NS2 的阳性和阴性预测值均大于 95%,患病率高于或低于 20%。测量特异性抗梅毒螺旋体 IgG 的鞘内合成 AI 是一种具有高度特异性的新的神经梅毒诊断工具。由于非特异性或非敏感性检测,神经梅毒的诊断缺乏金标准,本文提出了一种新的具有高度特异性的神经梅毒诊断工具。该新检测通过 ELISA 检测特定抗 IgG 的鞘内合成指数。